摘 要 目的：观察舒泌通胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症(BPH)的临床疗效。方法：将118例BPH患者随机分为治疗组和对照组各59例，治疗组口服舒泌通胶囊和盐酸坦索罗辛缓释胶囊，对照组仅口服盐酸坦索罗辛缓释胶囊，均连续治疗3个月，观察临床评价指标、临床疗效、中医证候积分和不良反应。结果：治疗组国际前列腺症状评分、生命质量评分等临床评价指标、临床疗效、中医证候积分均优于对照组(均P<0.05)。结论：舒泌通胶囊联合盐酸坦索罗辛缓释胶囊对改善BPH的尿频、尿急等症状临床疗效明显，不良反应少，值得临床进一步试验。

    关键词 舒泌通胶囊 坦索罗辛 良性前列腺增生症 尿频 尿急

    中图分类号：R286； R697.32 文献标志码：A 文章编号：1006-1533(2022)11-0025-04

    引用本文 林钿. 舒泌通胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症的临床疗效观察[J]. 上海医药， 2022， 43(11)： 25-28.

    Clinical efficacy of Shumitong capsule combined with tamsulosin hydrochloride sustained-release capsule in the treatment of benign prostatic hyperplasia

    LIN Dian(Department of Urology， Southern Theater General Hospital， Chinese People’s Liberation Army， Guangzhou 510010， China)

    ABSTRACT Objective： To observe the clinical efficacy of Shumitong capsule combined with tamsulosin hydrochloride sustained-release capsule in the treatment of benign prostatic hyperplasia (BPH). Methods： One hundred and eighteen patients with BPH were randomly divided into a treatment group and a control group with 59 cases each. The treatment group was treated with Shumitong capsule and tamsulosin hydrochloride sustained-release capsule while the control group only with tamsulosin hydrochloride sustained-release capsule. The treatment was lasted for 3 months and the clinical evaluation indexes ......